Yosuke Kawashima

1.1k total citations
41 papers, 721 citations indexed

About

Yosuke Kawashima is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yosuke Kawashima has authored 41 papers receiving a total of 721 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Yosuke Kawashima's work include Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (15 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Yosuke Kawashima is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (15 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Yosuke Kawashima collaborates with scholars based in Japan and United States. Yosuke Kawashima's co-authors include Shunichi Sugawara, Kyoji Tsurumi, Tomoiki Aiba, Yutaka Domeki, Keisuke Terayama, Yukihiro Toi, Yuichiro Kimura, Ryohei Saito, Atsushi Nakamura and Yoshihiro Honda and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Yosuke Kawashima

37 papers receiving 716 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yosuke Kawashima Japan	11	605	339	112	77	74	41	721
Anika E. Adeni United States	10	560 0.9×	249 0.7×	161 1.4×	45 0.6×	52 0.7×	19	635
Audrey Simonaggio France	10	445 0.7×	278 0.8×	82 0.7×	104 1.4×	45 0.6×	23	567
Junxun Ma China	18	596 1.0×	373 1.1×	135 1.2×	124 1.6×	55 0.7×	45	796
Xiao-Jing Du China	8	497 0.8×	194 0.6×	103 0.9×	67 0.9×	44 0.6×	9	677
Hayato Kawachi Japan	12	549 0.9×	435 1.3×	88 0.8×	92 1.2×	46 0.6×	35	711
Donald Woytowitz United States	11	477 0.8×	397 1.2×	146 1.3×	172 2.2×	36 0.5×	19	731
P. Jacoulet France	13	577 1.0×	481 1.4×	76 0.7×	147 1.9×	103 1.4×	53	823
Kuninobu Kanai Japan	10	435 0.7×	316 0.9×	98 0.9×	71 0.9×	47 0.6×	24	622
Aliyah Pabani Canada	13	629 1.0×	533 1.6×	82 0.7×	80 1.0×	62 0.8×	32	814
Gerry Gin Wai Kwok China	7	343 0.6×	109 0.3×	131 1.2×	79 1.0×	67 0.9×	10	518

Countries citing papers authored by Yosuke Kawashima

Since Specialization

Citations

This map shows the geographic impact of Yosuke Kawashima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yosuke Kawashima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yosuke Kawashima more than expected).

Fields of papers citing papers by Yosuke Kawashima

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yosuke Kawashima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yosuke Kawashima. The network helps show where Yosuke Kawashima may publish in the future.

Co-authorship network of co-authors of Yosuke Kawashima

This figure shows the co-authorship network connecting the top 25 collaborators of Yosuke Kawashima. A scholar is included among the top collaborators of Yosuke Kawashima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yosuke Kawashima. Yosuke Kawashima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kanda, Shintaro, Seiji Niho, Takayasu Kurata, et al.. (2025). Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation. Clinical Cancer Research. 31(12). 2317–2326. 1 indexed citations

Inomata, Minehiko, Yosuke Kawashima, Ryota Saito, et al.. (2024). Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma. Cancer Diagnosis & Prognosis. 4(4). 515–520.

Kawashima, Yosuke, Yasuhiko Munakata, Yusuke Yamazaki, et al.. (2024). Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome. Cancer Reports. 7(7). e2145–e2145.

Murakami, Yosuke, Yosuke Kawashima, Yusuke Yamazaki, et al.. (2024). Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases. Cancer Reports. 7(2). e1981–e1981.

Tanaka, Hisashi, Tomonori Makiguchi, Takehiro Tozuka, et al.. (2024). Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01. European Journal of Cancer. 213. 115117–115117. 1 indexed citations

Hayashi, Hidetoshi, Makoto Nishio, Hiroaki Akamatsu, et al.. (2024). Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer. Cancer Research Communications. 4(11). 2858–2867. 2 indexed citations

Inomata, Minehiko, Yosuke Kawashima, Ryota Saito, et al.. (2023). A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202. Oncology Letters. 26(2). 334–334. 4 indexed citations

Kawashima, Yosuke, Osamu Ishimoto, Eisaku Miyauchi, et al.. (2023). Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101. Thoracic Cancer. 14(27). 2804–2810. 1 indexed citations

Sugisaka, Jun, Yukihiro Toi, Yosuke Kawashima, et al.. (2023). Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge. Thoracic Cancer. 14(31). 3140–3146. 1 indexed citations

10.

Okuma, Yusuke, Kaoru Kubota, Mototsugu Shimokawa, et al.. (2023). First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations. JAMA Oncology. 10(1). 43–43. 39 indexed citations

11.

Hasegawa, Tsukasa, Ryo Ariyasu, Hisashi Tanaka, et al.. (2023). Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02). Cancer Chemotherapy and Pharmacology. 92(1). 29–37. 6 indexed citations

12.

Shiraishi, Yoshimasa, Takaaki Tokito, Ryo Toyozawa, et al.. (2023). Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report. Journal of Thoracic Oncology. 19(2). 337–343. 18 indexed citations

13.

Shimokawa, Tsuneo, Yuichi Takiguchi, Toshihiro Misumi, et al.. (2022). A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630. Clinical Cancer Research. 28(20). 4402–4409. 19 indexed citations

14.

Aiba, Tomoiki, Jun Sugisaka, Hisashi Shimizu, et al.. (2021). Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers. PLoS ONE. 16(11). e0260500–e0260500. 6 indexed citations

15.

Kawashima, Yosuke, et al.. (2021). Development and evaluation of a novel quenching probe PCR (GENECUBE) assay for rapidly detecting and distinguishing between Chlamydia pneumoniae and Chlamydia psittaci. Journal of Microbiological Methods. 184. 106212–106212. 5 indexed citations

16.

Toi, Yukihiro, Yuichiro Kimura, Yutaka Domeki, et al.. (2019). Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.. PubMed Central. 36(1). 74–78. 6 indexed citations

17.

Harada, Toshiyuki, Yosuke Kawashima, Yasuko Fujita, et al.. (2019). P1.01-08 Randomized Phase II Trial of CBDCA+nab-PTX vs CDDP+GEM in Patients with Chemo-Naïve Squamous Cell Lung Cancer: NJLCG1302. Journal of Thoracic Oncology. 14(10). S357–S357. 2 indexed citations

18.

Toi, Yukihiro, Shunichi Sugawara, Mari Aso, et al.. (2019). P1.16-29 Profiling Immune-Related Adverse Events (irAEs) in Patients with Anti-PD-1 for Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S598–S599. 1 indexed citations

19.

Uemura, Keiichi, Yosuke Kawashima, Shigeyuki Notake, et al.. (2019). Evaluation of performance of the GENECUBE assay for rapid molecular identification of Staphylococcus aureus and methicillin resistance in positive blood culture medium. PLoS ONE. 14(7). e0219819–e0219819. 10 indexed citations

20.

Kawashima, Yosuke, Akira Inoue, Shunichi Sugawara, et al.. (2014). Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802. Respiratory Investigation. 52(3). 190–194. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact